On 25 November 2025, the Ukrainian House hosted a gala ceremony to award the winners of the annual competition for professionals in the Ukrainian pharmaceutical industry, Panacea-2025, the main national event that recognises market leaders, innovations and industry achievements.
The ceremony was traditionally hosted by Timur Miroshnichenko, and the musical atmosphere of the evening was created by the band KADNAY.
The pharmaceutical industry in 2025: a year of courage, innovation and resilience
The awards ceremony brought together the leading companies, experts and innovators of the year.
In 2025, the Ukrainian pharmaceutical industry continues to operate in conditions of full-scale war and economic instability. Despite the pressure of circumstances, the market demonstrates a unique ability to adapt: companies invest in innovation, develop new approaches to products and services, implement digital solutions and support patient access to quality treatment.
This year’s ceremony was an evening of gratitude to all those who are making the Ukrainian healthcare system stronger and the pharmaceutical industry more competitive on a global level. Before announcing the winners, guests honoured the defenders of Ukraine with a minute of silence.
Winners of Panacea-2025
COMPANY OF THE YEAR
AI Excellence Award, Artificial Intelligence in Pharmacy
Winner: Roche
The company was recognised for its breakthrough in the application of artificial intelligence and the implementation of the project ‘Screening for diabetic retinopathy using AI’ — an innovation that gives patients access to fast and accurate diagnostics.
Investors in innovative treatment during wartime. International sponsors of clinical trials
Winner: MSD
The company was recognised for its continued support of clinical trials in Ukraine, increased investment in scientific programmes, and ensuring patients have access to modern treatments even during wartime.
PROJECT OF THE YEAR
Introduction of eCTD in Ukraine
Winner: State Expert Centre of the Ministry of Health of Ukraine
Ukraine has switched to the international format of registration dossiers eCTD, used by the EU, the US and leading regulators around the world, in record time. This step has already been recognised as one of the most important digital breakthroughs in Ukrainian pharmaceuticals.
EDUCATIONAL PROJECT OF THE YEAR
Polpharma Academy
The project was recognised for creating a modern interactive educational space for doctors with a focus on practice, professional support and uniting the medical community around knowledge and development.
DRUG OF THE YEAR — OVER-THE-COUNTER GROUP
2025 winners:
• AMIKSIN IS, Interchem
• PROKTOZAN NEO, STADA
• LAFEROBION, STADA
• NIKSAR, Berlin-Chemie Menarini
• HILO-KOMOD, Sona Exim
These drugs have become reliable ‘first-line solutions’ for patients in 2025.
Dynamic leader in the low-cost segment
Winner: PULMOBRIZ, MOVIHealth
The drug was recognised for its high efficacy, affordability and significant contribution to the treatment of seasonal respiratory diseases.
Panacea-2025 was made possible thanks to the support of:
• Analytical partners: IQVIA, SMD, Business Credit
• Professional associations: AIMP, AVLU, APRAD, APAU, Association of Medical Device Market Operators, Pharmaceutical League of Ukraine, Ukrainian Association of Evidence-Based Healthcare
• Legal partner: GelOn
• Tourism partner: DinAdis
• Media partners: Pharmaceutical Industry, Interfax-Ukraine
• Organiser: Zdorovo production company
This year’s Panacea has once again proven that the Ukrainian pharmaceutical industry is not just holding its own during the war — it is growing, reforming and boldly implementing global standards.
Innovative solutions, educational projects, support for clinical research and modern approaches to treatment — all this is shaping a new, strong and competitive Ukrainian pharmaceutical industry.
The organisers of the competition thanked all partners and participants for their contribution to the development of the industry and invited the community to the Panacea-2026 ceremony.
Interfax-Ukraine is the information partner of the Panacea Award
Since the beginning of 2024, medicines produced in India have accounted for 8.3% of the total volume of medicines imported to Ukraine.
The State Service for Medicinal Products and Drug Control (Goslexluzhba) informed Interfax-Ukraine that since the beginning of 2024, 3213 series (32824807 packages) from 65 Indian pharmaceutical manufacturers have been submitted for state quality control, which makes up 8.3% of the total volume of medicines imported to Ukraine.
At the same time during 2022-2023 10924 series of medicinal products manufactured in India were submitted for state quality control, including 4715 in 2022 and 6209 in 2023, which is 54705914 and 51309132 packages respectively.
In addition, the State Service of Medicinal Products with reference to the data of the State Register of Medicinal Products reported that since the beginning of 2024 Indian pharmaceutical manufacturers have registered in Ukraine a little more than 100 drugs (excluding active pharmaceutical ingredients, API – IF-U), currently in Ukraine are registered 1999 drugs manufactured in India, in 2023 in Ukraine were registered 1895 Indian drugs, in 2022 – 1709, in 2021 – 1472, in 2020 – 1165.
Thus, the dynamics of registration of Indian medicinal products in Ukraine over the last five years is slowing down: if the number of registered medicinal products manufactured in India in 2021 was 26.2% higher than a year earlier, then at the end of 2023 – only by 10.9%.
The production of basic pharmaceuticals in Ukraine in January-August 2019 increased by 8.8% compared to the same period last year, the State Statistics Service has reported. According to the report, in particular, production of drugs packaged for retail sale containing mixed or unmixed products increased by 5.6% in January-August compared to the same period of the previous year.
At the same time, the production of medicines containing antibiotics decreased by 3.1% compared with January-August 2018. The production of drugs intended for therapeutic or prophylactic use and containing corticosteroid hormones, their derivatives and structural analogues that do not contain antibiotics, fell by 15%, respectively.
As reported, production of basic pharmaceutical goods and pharmaceuticals in Ukraine in January-August 2018 decreased by 2.2% compared to the same period in 2017.
The Embassy of India in Kyiv in cooperation with the Pharmaceuticals Export Promotion Council of India (Pharmexcil) and the Indian Pharmaceutical Manufacturers Association (IPMA) will hold an annual business seminar in Ukraine to promote and demonstrate the potential of India in the pharmaceutical manufacturing sectors, Indian Ambassador to Ukraine Partha Satpathy has stated at a press conference at Interfax-Ukraine. “Pharmexcil is the Pharmaceuticals Export Promotion Council of India. The main task of this organization is to unite all important pharmaceutical manufacturers in India. The council cooperates with the government, represents the interests of manufacturers in exports, in particular brings pharmaceutical products in compliance with the requirements of the WHO and the importing country,” the ambassador said.
President of the Indian Pharmaceutical Manufacturers Association (IPMA) Dr. Menon, in turn, said that Pharmexcil plans to present several projects in Ukraine.
“Pharmexcil wants to find partners in Ukraine in the field of Ayurveda, clinical trials and create a joint venture for production of medicines,” he said.
The Indian ambassador noted that India is the third largest exporter of pharmaceutical products to Ukraine following Germany and France in terms of value, while Indian pharmaceutical companies supply high-quality products at a very good and competitive price.
